Inhibition of acute complement responses towards bolus-injected nanoparticles using targeted short-circulating regulatory proteins – Nature Nanotechnology

La-Beck, N. M., Islam, M. R. & Markiewski, M. M. Nanoparticle-induced complement activation: implications for cancer nanomedicine. Front. Immunol. 11, 603039 (2020).

Article  CAS  Google Scholar 

Moghimi, S. M., Simberg, D., Papini, E. & Farhangrazi, Z. S. Complement activation by drug carriers and particulate pharmaceuticals: principles, challenges and opportunities. Adv. Drug Deliv. Rev. 157, 83–95 (2020).

Article  CAS  Google Scholar 

Ricklin, D., Hajishengallis, G., Yang, K. & Lambris, J. D. Complement: a key system for immune surveillance and homeostasis. Nat. Immunol. 11, 785–797 (2010).

Article  CAS  Google Scholar 

Szebeni, J., Simberg, D., Gonzalez-Fernandez, A., Barenholz, Y. & Dobrovolskaia, M. A. Roadmap and strategy for overcoming infusion reactions to nanomedicines. Nat. Nanotechnol. 13, 1100–1108 (2018).

Article  CAS  Google Scholar 

Moghimi, S. M. et al. Material properties in complement activation. Adv. Drug Deliv. Rev. 63, 1000–1007 (2011).

Article  CAS  Google Scholar 

Tavano, R. et al. C1q-mediated complement activation and C3 opsonization trigger recognition of stealth poly(2-methyl-2-oxazoline)-coated cilica nanoparticles by human phagocytes. ACS Nano 12, 5834–5847 (2018).

Article  CAS  Google Scholar 

Inturi, S. et al. Modulatory role of surface coating of superparamagnetic iron oxide nanoworms in complement opsonization and leukocyte pptake. ACS Nano 9, 10758–10768 (2015).

Article  CAS  Google Scholar 

Dobrovolskaia, M. A., Aggarwal, P., Hall, J. B. & McNeil, S. E. Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol. Pharm. 5, 487–495 (2008).

Article  CAS  Google Scholar 

Ricklin, D. & Lambris, J. D. Complement in immune and inflammatory disorders: pathophysiological mechanisms. J. Immunol. 190, 3831–3838 (2013).

Article  CAS  Google Scholar 

Moghimi, S. M. Cancer nanomedicine and the complement system activation paradigm: anaphylaxis and tumour growth. J. Control. Release 190, 556–562 (2014).

Article  CAS  Google Scholar 

Forneris, F. et al. Regulators of complement activity mediate inhibitory mechanisms through a common C3b-binding mode. EMBO J. 35, 1133–1149 (2016).

Article  CAS  Google Scholar 

Schmidt, C. Q., Lambris, J. D. & Ricklin, D. Protection of host cells by complement regulators. Immunol. Rev. 274, 152–171 (2016).

Article  CAS  Google Scholar 

Zipfel, P. F. & Skerka, C. Complement regulators and inhibitory proteins. Nat. Rev. Immunol. 9, 729–740 (2009).

Article  CAS  Google Scholar 

Morgan, B. P. & Harris, C. L. Complement, a target for therapy in inflammatory and degenerative diseases. Nat. Rev. Drug Discov. 14, 857–877 (2015).

Article  CAS  Google Scholar 

Mastellos, D. C., Ricklin, D. & Lambris, J. D. Clinical promise of next-generation complement therapeutics. Nat. Rev. Drug Discov. 18, 707–729 (2019).

Article  CAS  Google Scholar 

Smith, G. P. & Smith, R. A. Membrane-targeted complement inhibitors. Mol. Immunol. 38, 249–255 (2001).

Article  CAS  Google Scholar 

Gaikwad, H. et al. Complement inhibitors block complement C3 opsonization and improve targeting selectivity of nanoparticles in blood. Bioconjugate Chem. 31, 1844–1856 (2020).

Article  CAS  Google Scholar 

Gifford, G. et al. Complement therapeutics meets nanomedicine: overcoming human complement activation and leukocyte uptake of nanomedicines with soluble domains of CD55. J. Control. Release 302, 181–189 (2019).

Article  CAS  Google Scholar 

Belling, J. N. et al. Stealth immune properties of graphene oxide enabled by surface-bound complement factor H. ACS Nano 10, 10161–10172 (2016).

Article  CAS  Google Scholar 

Wang, Z. et al. Combating complement’s deleterious effects on nanomedicine by conjugating complement regulatory proteins to nanoparticles. Adv. Mater. 34, e2107070 (2022).

Article  Google Scholar 

Souza, D. G., Esser, D., Bradford, R., Vieira, A. T. & Teixeira, M. M. APT070 (Mirococept), a membrane-localised complement inhibitor, inhibits inflammatory responses that follow intestinal ischaemia and reperfusion injury. Br. J. Pharmacol. 145, 1027–1034 (2005).

Article  CAS  Google Scholar 

White, J. et al. Biological activity, membrane-targeting modification, and crystallization of soluble human decay accelerating factor expressed in E. coli. Protein Sci. 13, 2406–2415 (2004).

Article  CAS  Google Scholar 

Bechtler, C. et al. Complement-regulatory biomaterial coatings: activity and selectivity profile of the factor H-binding peptide 5C6. Acta Biomater. 155, 123–138 (2023).

Article  CAS  Google Scholar 

Hare, J. I. et al. Challenges and strategies in anti-cancer nanomedicine development: an industry perspective. Adv. Drug Deliv. Rev. 108, 25–38 (2017).

Article  CAS  Google Scholar 

Benamu, E. & Montoya, J. G. Infections associated with the use of eculizumab: recommendations for prevention and prophylaxis. Curr. Opin. Infect. Dis. 29, 319–329 (2016).

Article  CAS  Google Scholar 

Barnum, S. R. Therapeutic inhibition of complement: well worth the risk. Trend Pharmacol. Sci. 38, 503–505 (2017).

Article  CAS  Google Scholar 

van den Elsen, J. M. & Isenman, D. E. A crystal structure of the complex between human complement receptor 2 and its ligand C3d. Science 332, 608–611 (2011).

Article  Google Scholar 

Farries, T. C., Seya, T., Harrison, R. A. & Atkinson, J. P. Competition for binding sites on C3b by CR1, CR2, MCP, factor B and factor H. Complement Inflamm. 7, 30–41 (1990).

Article  CAS  Google Scholar 

Holers, M. et al. The human complement receptor type 2 (CR2)/CR1 fusion protein TT32, a targeted inhibitor of the classical and alternative pathway C3 convertases, prevents arthritis in active immunization and passive transfer models and acts by CR2-dependent targeting of CR1 regulatory activity. Immunobiology 217, 1210–1210 (2012).

Article  Google Scholar 

Holers, V. M., Rohrer, B. & Tomlinson, S. CR2-mediated targeting of complement inhibitors: bench-to-bedside using a novel strategy for site-specific complement modulation. Adv. Exp. Med. Biol. 735, 137–154 (2013).

Article  CAS  Google Scholar 

Huang, Y. X., Qiao, F., Atkinson, C., Holers, V. M. & Tomlinson, S. A novel targeted inhibitor of the alternative pathway of complement and its therapeutic application in ischemia/reperfusion injury. J. Immunol. 181, 8068–8076 (2008).

Article  CAS  Google Scholar 

Risitano, A. M. et al. The complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment. Blood 119, 6307–6316 (2012).

Article  CAS  Google Scholar 

Tomlinson, S. & Thurman, J. M. Tissue-targeted complement therapeutics. Mol. Immunol. 102, 120–128 (2018).

Article  CAS  Google Scholar 

Risitano, A. M. et al. Safety and pharmacokinetics of the complement inhibitor TT30 in a phase I trial for untreated PNH patients. Blood 126, 2137 (2015).

Article  Google Scholar 

Fridkis-Hareli, M. et al. The human complement receptor type 2 (CR2)/CR1 fusion protein TT32, a novel targeted inhibitor of the classical and alternative pathway C3 convertases, prevents arthritis in active immunization and passive transfer mouse models. Mol. Immunol. 105, 150–164 (2019).

Article  CAS  Google Scholar 

Song, H., Qiao, F., Atkinson, C., Holers, V. M. & Tomlinson, S. A complement C3 inhibitor specifically targeted to sites of complement activation effectively ameliorates collagen-induced arthritis in DBA/1J mice. J. Immunol. 179, 7860–7867 (2007).

Article  CAS  Google Scholar 

Kim, Y. U. et al. Mouse complement regulatory protein Crry/p65 uses the specific mechanisms of both human decay-accelerating factor and membrane cofactor protein. J. Exp. Med. 181, 151–159 (1995).

Article  CAS  Google Scholar 

Benasutti, H. et al. Variability of complement response toward preclinical and clinical nanocarriers in the general population. Bioconjugate Chem. 28, 2747–2755 (2017).

Article  CAS  Google Scholar 

Berger, N. et al. New analogs of the complement C3 inhibitor compstatin with increased solubility and improved pharmacokinetic profile. J. Med. Chem. 61, 6153–6162 (2018).

Article  CAS  Google Scholar 

Lamers, C. et al. Insight into mode-of-action and structural determinants of the compstatin family of clinical complement inhibitors. Nat. Commun. 13, 5519 (2022).

Article  CAS  Google Scholar 

Guthridge, J. M. et al. Epitope mapping using the X-ray crystallographic structure of complement receptor type 2 (CR2)/CD21: identification of a highly inhibitory monoclonal antibody that directly recognizes the CR2-C3d interface. J. Immunol. 167, 5758–5766 (2001).

Article  CAS  Google Scholar 

Chen, F. et al. Complement proteins bind to nanoparticle protein corona and undergo dynamic exchange in vivo. Nat. Nanotechnol. 12, 387–393 (2017).

Article  CAS  Google Scholar 

Venkatesh, Y. P., Minich, T. M., Law, S. K. & Levine, R. P. Natural release of covalently bound C3b from cell surfaces and the study of this phenomenon in the fluid-phase system. J. Immunol. 132, 1435–1439 (1984).

Article  CAS  Google Scholar 

Li, Y. et al. Complement opsonization of nanoparticles: differences between humans and preclinical species. J. Control. Release 338, 548–556 (2021).

Article  CAS  Google Scholar 

Hardy, M. P., Rowe, T. & Wymann, S. Soluble complement receptor 1 therapeutics. J. Immunol. Sci. 6, 1–17 (2022).

Article  Google Scholar 

Voorhees, A. B., Baker, H. J. & Pulaski, E. J. Reactions of albino rats to injections of dextran. Proc. Soc. Exp. Biol. Med. 76, 254–256 (1951).

Article  CAS  Google Scholar 

Dezsi, L. et al. Complement activation-related pathophysiological changes in anesthetized rats: activator-dependent variations of symptoms and mediators of pseudoallergy. Molecules 24, 3283 (2019).

Article  CAS  Google Scholar 

Timotius, I. K. et al. Combination of defined catwalk gait parameters for predictive locomotion recovery in experimental spinal cord injury rat models. eNeuro 8, 0497-20.2021 (2021).

Chen, E. et al. Premature drug release from polyethylene glycol (PEG)-coated liposomal doxorubicin via formation of the membrane attack complex. ACS Nano 14, 7808–7822 (2020).

Article  CAS  Google Scholar 

Munter, R. et al. Unravelling heterogeneities in complement and antibody opsonization of individual liposomes as a function of surface architecture. Small 18, e2106529 (2022).

Article  Google Scholar 

Vu, V. P. et al. Immunoglobulin deposition on biomolecule corona determines complement opsonization efficiency of preclinical and clinical nanoparticles. Nat. Nanotechnol. 14, 260–268 (2019).

Article  CAS  Google Scholar 

Wang, G. et al. In vitro and in vivo differences in murine third complement component (C3) opsonization and macrophage/leukocyte responses to antibody-functionalized iron oxide nanoworms. Front. Immunol. 8, 151 (2017).

Google Scholar 

Wang, G. et al. Activation of human complement system by dextran-coated iron oxide nanoparticles is not affected by dextran/Fe ratio, hydroxyl modifications, and crosslinking. Front. Immunol. 7, 418 (2016).

Article  Google Scholar 

Moghimi, S. M. & Simberg, D. Critical issues and pitfalls in serum and plasma handling for complement analysis in nanomedicine and bionanotechnology. Nano Today 44, 101479 (2022).

Article  CAS  Google Scholar 

Wu, L.-P. et al. Dendrimer end-terminal motif-dependent evasion of human complement and complement activation through IgM hitchhiking. Nat. Commun. 12, 4858 (2021).

Article  CAS  Google Scholar 

Wang, G. et al. High-relaxivity superparamagnetic iron oxide nanoworms with decreased immune recognition and long-circulating properties. ACS Nano 8, 12437–12449 (2014).

Article  CAS  Google Scholar